retatrutide phase 3 trial just delivered the most powerful weight loss data ever recorded in a obesity trial. At 104 weeks, participants on the 12 mg dose lost an average of 85 pounds Phase III retatrutide study demonstrates
Description
The newest kid on the block The ATTAIN-2 trial was conducted across 10 countries and involved more than 1,600 people who were obese or overweight with type 2 diabetes
The sensitivity of the vagal nerve to estradiol fluctuates through the estrous cycle, as ER expression changes in response to circulating estradiol levels (140)
Bickel, professor, Fralin Biomedical Research Institute Alexandra G
Gene therapy with novel adeno-associated virus vectors substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia
